La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mesa Laboratories a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mesa Laboratories..

Mesa Laboratories (NASDAQ:MLAB) Azioni, Catena delle Opzioni

Mesa Laboratories

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Mesa Laboratories Inc

Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) with a Outperform and raises the price target from $120 to $160.

News

Price Target

Analyst Ratings

MLAB

Evercore ISI Group Maintains Outperform on Mesa Laboratories, Raises Price Target to $160

Wells Fargo analyst Brandon Couillard initiates coverage on Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) with a Underweight rating and announces Price Target of $120.

Initiation

Wells Fargo Initiates Coverage On Mesa Laboratories with Underweight Rating, Announces Price Target of $120

Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) with a Outperform and raises the price target from $106 to $120.

Evercore ISI Group Maintains Outperform on Mesa Laboratories, Raises Price Target to $120

Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.44 by 40.91 percent. The company reported quarterly sales of $58.17 million which beat the analyst consensus estimate of $55.74 million by 4.35 percent. This is a 14.86 percent increase over sales of $50.65 million the same period last year.

Earnings

CORRECTION: Mesa Laboratories Q1 2025 EPS $0.62 Beats $0.44 Estimate, Sales $58.17M Beat $55.74M Estimate

Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) with a Outperform and lowers the price target from $120 to $106.

Evercore ISI Group Maintains Outperform on Mesa Laboratories, Lowers Price Target to $106

WIIM

Mesa Laboratories shares are trading higher after the company reported better-than-expected Q4 sales results.

Mesa Laboratories Q4 2024 GAAP EPS $(47.20) May Not Be Comparable To $(0.12) Estimate, Sales $58.904M Beat $55.275M Estimate

Shares of SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares fell sharply during Friday's session after the company posted <a href="https://www.benzinga.com/news/earnings/24/05/39100292/sentinelone-reports-mixed-q1-results-eps-miss-sales-beat">mixed first-quarter results.</a>
SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SentinelOne shares dipped 15.9% to $16.35 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novo Integrated Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The company&#8217;s board is conducting a review to determine whether it is appropriate to increase the amount under the repurchase program.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) rose 79.5% to $464.77.</li>
<li>Digital Health Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAC#NASDAQ">DHAC</a>) gained 57.3% to $23.60.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) gained 51% to $3.89.</li>
<li>XChange Tec Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) gained 41.5% to $0.9691 after dipping 15% on Thursday.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) jumped 39.2% to $0.2226 after falling around 12% on Thursday.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) gained 30% to $0.4432.</li>
<li>LightInTheBox Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) rose 27.4% to $0.65.</li>
<li>Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) gained 26% to $6.57.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) rose 23% to $59.42 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>) shares climbed 21.6% to $27.38 after reporting strong quarterly results.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares gained 21.5% to $0.9602. Innovative Eyewear recently launched its Eddie Bauer Smart Eyewear collection.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) gained 19.2% to $8.38.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) rose 16.6% to $4.6310. BTIG analyst Thomas Shrader initiated coverage on AC Immune with a Buy rating and announced a price target of $8.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) gained 13.9% to $8.09. Larimar Therapeutics was selected by the FDA to participate in START Pilot Program for Nomlabofusp in Friedreich&#8217;s Ataxia.</li>
<li>DoubleDown Interactive Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) rose 13.1% to $13.80.</li>
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) jumped 11% to $19.35.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) gained 10.7% to $19.87 following a first-quarter earnings beat.</li>
<li>A2Z Smart Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZ#NASDAQ">AZ</a>) shares gained 10% to $0.44. </li>
<li>V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) rose 10% to $13.57 after the company appointed former Lululemon Chief Product Officer Michelle Choehas as the Global Brand President of Vans.</li>
<li>Elastic N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NASDAQ">ESTC</a>) gained 9.6% to $102.09 following a fourth-quarter earnings beat.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) gained 9% to $1.10 after the company and Galapagos entered a clinical collaboration to license Adaptimmune&#8217;s uza-cel in in head &amp; neck cancer.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) rose 8.6% to $170.04 after the company reported better-than-expected third-quarter earnings.</li>
<li>flyExclusive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#NASDAQ">FLYX</a>) climbed 7.6% to $5.64. flyExclusive announced the appointment of two key business leaders.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) rose 4.3% to $13.70. Asana posted a narrower-than-expected loss for its first quarter, while sales topped estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) fell 38.7% to $3.71.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares fell 38.1% to $1.0398 after gaining over 8% on Thursday.</li>
<li>Calidi Biotherapeutics, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) dipped 31.1% to $0.2073 after the company reported exercise of warrants for $2.1 million gross proceeds.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) shares dipped 26.2% to $228.83 after the company issued weak FY25 guidance.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 25.2% to $8.16. Summit Therapeutics jumped 272% on Thursday after the company&#8217;s Phase III HARMONi-2 trial met its primary endpoint.</li>
<li>Loop Media, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPTV#NYSE">LPTV</a>) fell 21.3% to $0.1817. Loop Media priced $2.45 million registered direct offering of 9.65 million shares of common stock at a price of $0.15 per share.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares fell 21.2% to $134.18. Dell reported upbeat earnings and sales results for the first quarter.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) fell 21% to $10.30. Lotus Technology recently reported a year-over-year increase in first-quarter sales results.</li>
<li>Montana Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) dipped 17.8% to $12.84.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) fell 16.7% to $0.2639 after gaining over 16% on Thursday.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) dipped 15.7% to $10.15.</li>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) fell 15.3% to $0.2546.</li>
<li>Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) fell 13.3% to $18.47 following first-quarter results.</li>
<li>JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) shares fell 12% to $1.1450 after gaining around 85% on Thursday.</li>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 11.9% to $0.7620. Momentus received Nasdaq deficiency notice due to delayed Form 10-Q.</li>
<li>Genfit S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) shares fell 11.7% to $5.27 after gaining 13% on Thursday.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 11.3% to $68.11 following worse-than-expected first-quarter earnings.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares fell 10.8% to $173.19 after the company issued weak revenue guidance.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) declined 10.6% to $15.20.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares declined 10.3% to $2.3420. OneMedNet shares jumped 34% on Thursday after the company announced that it has entered into a non-exclusive three-year Master Services Agreement with an undisclosed U.S.-based medical technology company.</li>
<li>Mesa Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) fell 10.1% to $99.19. Mesa Laboratories has delayed the release of its fourth-quarter and fiscal year 2024 financial results, originally scheduled for today.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) dipped 9.2% to $92.84.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) declined 9% to $95.84.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) fell 7.6% to $35.44. HP recently posted better-than-expected second-quarter financial results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) declined 7.2% to $768.22.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares declined 4.9% to $49.31 after the jury reached a verdict in Donald Trump&#8217;s hush money case.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38312420/how-to-earn-500-a-month-from-ford-stock-ahead-of-q1-earnings-report&#8221;&gt;&lt;em&gt; How To Earn $500 A Month From Ford Stock Ahead Of Q1 Earnings Report&lt;/em&gt;&lt;/a&gt;

Intraday Update

Markets

Movers

Trading Ideas

ACIU

ADAP

AIRJ

AMBA

AMSC

ASAN

BNAI

BURU

CLDI

DELL

DHAC

ESTC

FAAS

FLYX

FOXO

FTEL

GNFT

JCSE

KSCP

Kintara Therapeutics, Inc. - Common Stock

KTRA

LITB

LPTV

Larimar Therapeutics, Inc. - Common Stock

LRMR

LUCY

MNTS

MRVL

NVOS

ONMD

PLSE

SIFY

SMCI

SMFL

SMMT

VCNX

VEEV

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

The postponement is due to the ongoing year-end audit, which is finalizing calculations and technical accounting for previously announced impairments of long-lived assets and goodwill in the Clinical Genomics and Biopharmaceutical Development divisions, as well as the purchase accounting for the acquisition of GKE.
Mesa&#39;s Form 10-K filing deadline with the SEC is June 14, 2024.

Health Care

General

Mesa Laboratories Has Delayed The Release Of Its Fourth-quarter And Fiscal Year 2024 Financial Results, Originally Scheduled For Today

Mesa&#39;s Form 10-K will be filed the same day. The earnings announcement has been delayed as it&nbsp; finalizes the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to Clinical Genomics and Biopharmaceutical Development divisions.&nbsp;Mesa&#39;s Form 10-K filing deadline with the SEC is June 14, 2024.

Mesa Laboratories Revises Earnings Announcement Date For Q4 Results To May 31, 2024

Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) with a Outperform and raises the price target from $124 to $130.

Evercore ISI Group Maintains Outperform on Mesa Laboratories, Raises Price Target to $130

Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $0.19 by 963.16 percent. This is a 14.04 percent decrease over earnings of $2.35 per share from the same period last year. The company reported quarterly sales of $53.47 million which missed the analyst consensus estimate of $54.89 million by 2.59 percent. This is a 1.50 percent decrease over sales of $54.29 million the same period last year.

Mesa Laboratories Q3 Adjusted EPS $2.02 May Not Be Comparable To $0.19 Estimate, Sales $53.47M Miss $54.89M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.
&bull; Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) is projected to report quarterly earnings at $5.98 per share on revenue of $524.15 million.
&bull; Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report quarterly loss at $0.85 per share on revenue of $300.23 million.
&bull; Bowlero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) is estimated to report quarterly earnings at $0.12 per share on revenue of $300.52 million.
&bull; ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is estimated to report quarterly earnings at $1.21 per share on revenue of $2.00 billion.
&bull; Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $13.36 billion.
&bull; McDonald&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is likely to report quarterly earnings at $2.82 per share on revenue of $6.45 billion.
&bull; Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) is expected to report quarterly earnings at $0.55 per share on revenue of $4.20 billion.
&bull; IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is expected to report quarterly earnings at $2.11 per share on revenue of $889.85 million.
&bull; Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) is projected to report quarterly earnings at $4.75 per share on revenue of $17.11 billion.
&bull; Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) is projected to report quarterly loss at $0.03 per share on revenue of $38.94 million.
&bull; CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) is likely to report quarterly earnings at $1.10 per share on revenue of $2.95 billion.
&bull; Mitsubishi UFJ Finl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) is projected to report earnings for its third quarter.
&bull; Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) is estimated to report quarterly earnings at $1.22 per share on revenue of $1.06 billion.
&bull; Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) is likely to report earnings for its fourth quarter.
&bull; Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $54.89 million.
&bull; Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) is expected to report quarterly earnings at $3.00 per share on revenue of $3.20 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Bright Scholar Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEDU#NYSE">BEDU</a>) is projected to report earnings for its first quarter.
&bull; IRSA Inversiones y (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRS#NYSE">IRS</a>) is estimated to report earnings for its second quarter.
&bull; Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) is projected to report earnings for its fourth quarter.
&bull; BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $412.86 million.
&bull; Hillenbrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $777.81 million.
&bull; NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is estimated to report quarterly earnings at $3.63 per share on revenue of $3.40 billion.
&bull; Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) is likely to report quarterly loss at $0.06 per share on revenue of $368.89 million.
&bull; Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $160.51 million.
&bull; Kforce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NASDAQ">KFRC</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $363.36 million.
&bull; Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is estimated to report quarterly earnings at $4.09 per share on revenue of $2.51 billion.
&bull; Itau Unibanco Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITUB#NYSE">ITUB</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $7.99 billion.
&bull; United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $299.98 million.
&bull; Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $602.55 million.
&bull; Skyline Champion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $499.72 million.
&bull; AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $3.66 billion.
&bull; Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $1.68 billion.
&bull; Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $1.12 billion.
&bull; Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is estimated to report quarterly earnings at $1.48 per share on revenue of $482.21 million.
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $2.03 per share on revenue of $693.15 million.
&bull; Kimball Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $435.67 million.
&bull; Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $952.85 million.
&bull; ChampionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NASDAQ">CHX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $950.17 million.
&bull; Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) is estimated to report quarterly earnings at $1.43 per share on revenue of $2.95 billion.
&bull; Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $102.12 million.
&bull; Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $23.39 million.
&bull; Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is estimated to report quarterly earnings at $0.45 per share on revenue of $134.00 million.
&bull; Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $187.44 million.
&bull; Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) is estimated to report earnings for its fourth quarter.
&bull; Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $151.88 million.
&bull; Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $9.70 million.
&bull; FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $1.25 billion.
&bull; J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $362.88 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AMKR

BEDU

BOWL

BRBR

CHGG

COHR

FLXS

GBDC

GLAD

IDXX

ITUB

IVAC

JJSF

KFRC

MUFG

NSSC

NXPI

PLTR

RMBS

SPHR

VRNS

VRTX

Earnings Scheduled For February 5, 2024

Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) is set to give its latest quarterly earnings report on Monday, 2024-02-05. Here's what investors need to know before the announcement.
Analysts estimate that Mesa Laboratories will report an earnings per share (EPS) of $0.19. 
Mesa Laboratories bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $1.76, which was followed by a 1.53% increase in the share price the next day.
Here's a look at Mesa Laboratories's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>1.67</td>
<td>0.37</td>
<td>0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.91</td>
<td>1.77</td>
<td>1.94</td>
<td>2.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.53%</td>
<td>2.59%</td>
<td>-0.26%</td>
<td>1.86%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1706889653_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Mesa Laboratories were trading at $94.07 as of February 01. Over the last 52-week period, shares are down 48.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MLAB/earnings">To track all earnings releases for Mesa Laboratories visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Mesa Laboratories

Evercore ISI Group upgraded its rating of Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) to Outperform with a price target of $125.00, changing its price target from $100.00 to $125.00.
Shares of Mesa Laboratories are trading up 0.1% over the last 24 hours, at $97.23 per share.
A move to $125.00 would account for a 28.56% increase from the current share price.
<h3>About Mesa Laboratories</h3>
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators. It also provides testing and laboratory services, mainly to the dental industry; Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions; Calibration Solutions division develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes; and Clinical Genomics. Its geographical segments include United States and Foreign.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evercore ISI Group Upgrades Mesa Laboratories: Here's What You Need To Know

Evercore ISI Group analyst Vijay Kumar upgrades Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) from In-Line to Outperform and raises the price target from $100 to $125.

Upgrades

Evercore ISI Group Upgrades Mesa Laboratories to Outperform, Raises Price Target to $125

AAON

ACVA

ADEA

ADTN

ALTO

AMPY

AMRC

AOSL

AQST

ARKO

ATEC

ATIP

ATSG

AUGX

AXSM

AZPN

BCSF

BNTX

BWMN

CCCS

CHRS

CLLS

CLOV

COMP

CRGY

CRNT

CTRA

DCGO

DISH

DMRC

EOSE

Embraer-Empresa Brasileira De Aeronautica

EVCM

EVER

FANG

FENC

FGEN

FRPT

GATO

GMRE

GOOD

GORO

HALO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HNRG

ICHR

ICUI

INTR

ISPO

JELD

KIDS

KLXE

KRYS

LINC

MGNX

MTTR

Earnings Scheduled For November 6, 2023

Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $0.15 by 1173.33 percent. This is a 33.68 percent decrease over earnings of $2.88 per share from the same period last year. The company reported quarterly sales of $53.16 million which missed the analyst consensus estimate of $54.65 million by 2.72 percent. This is a 9.50 percent decrease over sales of $58.75 million the same period last year.

Mesa Laboratories Q2 EPS $1.91 May Not Be Comparable To $0.15 Estimate, Sales $53.16M Miss $54.65M Estimate

Mesa Laboratories Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels For €85M

The Nasdaq 100 closed higher by over 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company&rsquo;s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Cogent Communications </h3>
<ul>
<li>The Trade: Cogent Communications Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ccoi#NASDAQ">CCOI</a>) Chairman, CEO and President David Schaeffer <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 45,000 shares </a> at an average price of $66.87. The insider received around $3.01 million from selling those shares.</li>
<li>What&rsquo;s Happening: Cogent Communications shar reported better-than-expected second-quarter earnings results.</li>
<li>What Cogent Communications Does: Cogent carries over one fifth of the world&#39;s internet traffic over its network and is a broadband provider for businesses.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Weyerhaeuser</h3>
<ul>
<li>The Trade: Weyerhaeuser Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wy#NYSE">WY</a>) Senior Vice President Denise Merle <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 7,500 shares </a> at an average price of $32.29. The insider received around $242,152 from selling those shares.</li>
<li>What&rsquo;s Happening: Weyerhaeuser posted better-than-expected quarterly earnings.</li>
<li>What Weyerhaeuser Does: Weyerhaeuser ranks among the world&#39;s largest forest product companies.</li>
</ul>
<h3>Trimble </h3>
<ul>
<li>The Trade: Trimble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmb#NASDAQ">TRMB</a>) President and CEO Rob Painter <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 2,500 shares </a> at an average price of $50.34. The insider received around $125,850 from selling those shares.</li>
<li>What&rsquo;s Happening: Trimble posted upbeat second-quarter results.</li>
<li>What Trimble Does: Trimble Inc provides location-based solutions that are used in global positioning system (GPS), laser, optical and inertial technologies. Its products portfolio includes 3D laser scanning, flow and application control systems, monitoring systems, water management, and navigation infrastructure.</li>
</ul>
<h3>Mesa Laboratories </h3>
<ul>
<li>The Trade: Mesa Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlab#NASDAQ">MLAB</a>) Director Bradley John Schmieder <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 3,000 shares </a> at an average price of $123.32. The insider received around $369,965 from selling those shares.</li>
<li>What&rsquo;s Happening: Mesa Laboratories posted upbeat quarterly earnings.</li>
<li>What Mesa Laboratories Does: Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/23/09/34569273/top-5-tech-and-telecom-stocks-you-may-want-to-dump-in-q3"> Top 5 Tech And Telecom Stocks You May Want To Dump In Q3 </a>

Short Ideas

Small Cap

Insider Trades

Pre-Market Outlook

CCOI

TRMB

Cogent Communications, Trimble And 2 Other Stocks Insiders Are Selling

25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA

Earnings week ahead: NVIDIA, Target, Zoom Video, Snowflake and more

Earnings week ahead: Salesforce, Costco, Canopy Growth, Dell,  Dollar General, and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mesa Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlab-stock-quote/">MLAB</a>) just reported results for the fourth quarter of 2024.<ul><li>Mesa Laboratories reported earnings per share of $2.77. This was above the analyst estimate for EPS of $2.33.</li><li>The company reported revenue of $58.90 million.</li><li>This was 6.57% better than the analyst estimate for revenue of $55.27 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/mlab-stock-earnings-mesa-laboratories-for-q4-of-2024/">MLAB Stock Earnings: Mesa Laboratories Beats EPS, Beats Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MLAB Stock Earnings: Mesa Laboratories Beats EPS, Beats Revenue for Q4 2024

Mesa Laboratories declares $0.16 dividend

Mesa Laboratories Non-GAAP EPS of $2.58, revenue of $58.17M

Small-cap and mid-cap Health Care has room to rally - Roth MKM

Conestoga Capital Advisors Q2 2024 Commentary

RMT: A Micro-Cap Equity Fund For Income Investors, With A Nearly 8% Yield And 12% Discount

Comments

Mesa Laboratories

Mesa Laboratories (MLAB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO